PegBio Co., Ltd. (SEHK: 2565)
Health Care · Biotechnology · CN
HK$4.69
-3.10% today · -91.1% 1Y
PegBio Co., Ltd. (SEHK: 2565) operates in the Biotechnology industry within the Health Care sector. The company is valued at $233.73M and employs 58 people.
Over the last twelve months the share price has lost 91.1%, trading between 4.50 and 77.00.
Tweenvest scores PegBio Co., Ltd. across four factors: quality 37/100, value 23/100. Its strongest factor is quality.
2565 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $233.73M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.85
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$77.00
- 52-week low
- HK$4.50
- Avg volume (3M)
- —
- Shares outstanding
- 391.09M
- Employees
- 58
- Next earnings
- —
About PegBio Co., Ltd.
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
- ISIN
- CNE100006T44
- Founded
- 2008
- Listed since
- May 27, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sutro Biopharma, Inc.NasdaqGM: STRO | $236.61M | $14.27 | -7.04% |
| Camp4 Therapeutics CorporationNasdaqGM: CAMP | $236.58M | $3.77 | -5.75% |
| InflaRx N.V.NasdaqGS: IFRX | $235.79M | $1.60 | +4.58% |
| Tetratherix LimitedASX: TTX | $234.75M | AU$6.34 | -1.71% |
| Alector, Inc.NasdaqGS: ALEC | $232.25M | $2.08 | +2.97% |
| EuBiologics Co., Ltd.KOSDAQ: A206650 | $230.18M | ₩8,420.00 | -0.36% |
| ProQR Therapeutics N.V.NasdaqCM: PRQR | $230.03M | $1.63 | -0.31% |
| Valerio Therapeutics Société anonymeENXTPA: ALVIO | $229.28M | €0.41 | +7.61% |
Figures last refreshed Oct 11, 2026.